Results 81 to 90 of about 51,116 (225)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension [PDF]

, 2017
The efficacy and safety of azilsartan medoxomil (AZL-M) were evaluated in African-American patients with hypertension in a 6-week, double-blind, randomized, placebo-controlled trial, for which the primary end point was change from baseline in 24-hour ...
Bakris, George L., Cao, Charlie, Handley, Alison, Johnson, Wallace, Kupfer, Stuart, Perez, Alfonso, Saunders, Elijah B., Sica, Domenic, Weber, Michael A., White, William B.   +9 more
core   +2 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure Valsartan heart failure trial (Val-HeFT) echocardiographic data [PDF]

, 2004
ObjectivesThe objective of this study was to test the hypothesis that the severity of left ventricular remodeling predicts the response to treatment and outcomes in chronic heart failure.BackgroundReversal of remodeling should produce the most favorable ...
Bechini, L., Bijttebier, J., Cormont, A., Guzmã, Hazeu, G., Hijbeek, R., Janssen, B., Pronk, A. A., Schlatter, N., Van Eupen, M., Van Ittersum, M. K., Werner, M., Zavattaro, Laura   +12 more
core   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure [PDF]

, 2017
Aims: It is unclear whether distinct pathophysiological processes are present among patients with acute heart failure (AHF), with and without diabetes.
Bloomfield, Daniel M., Cleland, John G.F., Cotter, Gad, Davison, Beth A., Demissei, Biniyam G., Dittrich, Howard, Ezekowitz, Justin A., Givertz, Michael M., Hillege, Hans L., Khan, Mohsin A.F., Metra, Marco, O'Connor, Christopher M., Ponikowski, Piotr, Sharma, Abhinav, Teerlink, John R., Tromp, Jasper, van Veldhuisen, Dirk J., Voors, Adriaan A.   +17 more
core   +2 more sources

Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.

Journal of the American College of Cardiology, 2019
BACKGROUND Myocardial fibrosis is an important pathophysiological mechanism underlying the development of heart failure (HF). Given the biochemical targets of sacubitril/valsartan, we hypothesized that circulating biomarkers reflecting the mechanisms ...
M. Zile, E. O’Meara, B. Claggett, M. Prescott, S. Solomon, K. Swedberg, M. Packer, J. McMurray, V. Shi, M. Lefkowitz, J. Rouleau   +10 more
semanticscholar   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Pharmacologic approaches against advanced glycation end products (ages) in diabetic cardiovascular disease [PDF]

, 2015
Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients.
Avtaar Singh, Sanjeet Singh, Chello, Massimo, DI DOMENICO, Fabio, Nappi, Francesco, Nenna, Antonio, Spadaccio, Cristiano, Sutherland, Fraser W   +6 more
core   +2 more sources

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]

, 2016
Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia, AIRE Study Group, Alexander, Alexander, Alexander, Alexander, Ashrafian, Bailey, Bailey, Basu, Beadle, Braunwald, Brown, Burgoyne, Chaitman, Chatterjee, Chung, CIBIS-II Study Group, Cleland, Clerc, Cohn, Cohn, Cohn, CONSENSUS Trial Study Group, Conway, Cook, Dai, Digitalis Investigation Group, Doenst, Dzau, Dzau, Faris, Flather, Follath, Foster, Fox, Fox, Fragasso, Furberg, Gheorghiade, Gladwin, Goffart, Granger, Greenberg, Guazzi, Guazzi, Heymans, Hobbs, Holubarsch, Horowitz, Horowitz, Kantor, Kapil, Kato, Kennedy, Kennedy, Kostis, Larsen, Lee, Lopaschuk, Luiken, Lundberg, Maher, Maier, Mancini, Mann, Mann, Massie, Mccormack, Mcdowell, Mcmurray, Mcmurray, Merit-Hf Study Group, Munzel, Munzel, Neglia, Neubauer, Ormerod, Packer, Packer, Paul, Pawson, Pfeffer, Pfeffer, Pitt, Pitt, Rathore, Rauchhaus, Redfield, Rona, Sack, Sarraf, Schmidt-Schweda, Schrauwen, Schwarz, Shah, Shah, Siddiqi, Singh, SOLVD Investigators, Stanley, Swedberg, Szwed, Taylor, Teerlink, Tilemann, Torre-Amione, Totzeck, Turcani, Unger, Van Der Vusse, Van Faassen, Vardeny, Webb, Yin, Yusuf, Zamani, Zannad, Zannad, Zhang   +119 more
core   +1 more source

Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis.

JACC. Heart failure, 2020
OBJECTIVES The purpose of this study was to investigate the effect of sacubitril/valsartan therapy on sudden cardiac death (SCD) according to the use of and eligibility for an implantable cardioverter-defibrillator (ICD), stratified by heart failure ...
Luis E. Rohde, Neal A. Chatterjee, M. Vaduganathan, B. Claggett, M. Packer, Akshay S. Desai, M. Zile, J. Rouleau, K. Swedberg, M. Lefkowitz, V. Shi, J. McMurray, S. Solomon   +12 more
semanticscholar   +1 more source